Empagliflozin placebo

DRUG6 trials

Conditions

Alzheimer DiseaseChronic Kidney DiseaseDiabetes Mellitus, Type IIDyslipidemiaDyslipidemia Associated With Type II Diabetes MellitusType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

CompletedNCT05254002

BayerChronic Kidney Disease, Type 2 Diabetes Mellitus

Start: 2022-06-23End: 2025-03-17Updated: 2026-07-13

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

Not yet recruitingNCT07756294

Wake Forest University Health SciencesAlzheimer Disease

Start: 2026-09-01End: 2028-04-01Target: 30Updated: 2026-08-25

Phase 3

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

RecruitingNCT04602754

EMSDyslipidemia Associated With Type II Diabetes Mellitus

Start: 2023-12-01End: 2027-09-30Target: 228Updated: 2025-12-08

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

NCT04603508

EMSDyslipidemia, Type 2 Diabetes Mellitus

Start: 2023-03-31End: 2025-08-31Target: 240Updated: 2022-08-05

Phase 4

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

TerminatedNCT02985242

Hannover Medical SchoolDiabetes Mellitus, Type II

Start: 2017-06-12End: 2018-08-16Updated: 2018-09-27

Unknown Phase

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

CompletedNCT02792400

University Hospital, Gentofte, CopenhagenType 2 Diabetes

Start: 2016-05-31End: 2018-07-31Updated: 2020-04-08

2026-06-05

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone

Journal of the American Society of Nephrology2026-03-29

Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial

Nephrology Dialysis Transplantation2026-03-27

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.

UNC Libraries2026-01-06

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.

2025-12-011 citations

Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.

2025-11-071 citations

Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both

Journal of the American Society of Nephrology2025-11-06

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.

2025-08-019 citations

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

New England Journal of Medicine2025-06-05117 citations

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Nephrology Dialysis Transplantation2024-11-1232 citations

Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure

Circulation2024-09-2839 citations

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Nephrology Dialysis Transplantation2024-06-1159 citations

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).

2023-07-316 citations

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Nephrology Dialysis Transplantation2022-06-14148 citations